163 related articles for article (PubMed ID: 16757681)
41. Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies.
Dong Z; Song JY; Thieme E; Anderson A; Oh E; Cheng WA; Kuang BZ; Lee V; Zhang T; Wang Z; Szymura S; Smith DL; Zhang J; Nian W; Zheng X; He F; Zhou Q; Cha SC; Danilov AV; Qin H; Kwak LW
Blood Adv; 2023 Mar; 7(6):918-932. PubMed ID: 36469551
[TBL] [Abstract][Full Text] [Related]
42. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S
Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
[TBL] [Abstract][Full Text] [Related]
43. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.
Bowles JA; Weiner GJ
J Immunol Methods; 2005 Sep; 304(1-2):88-99. PubMed ID: 16109421
[TBL] [Abstract][Full Text] [Related]
44. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).
Williams EL; Tutt AL; French RR; Chan HT; Lau B; Penfold CA; Mockridge CI; Roghanian A; Cox KL; Verbeek JS; Glennie MJ; Cragg MS
Eur J Immunol; 2012 Aug; 42(8):2109-20. PubMed ID: 22760702
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
[TBL] [Abstract][Full Text] [Related]
46. Characterization and crystallization of soluble human Fc gamma receptor II (CD32) isoforms produced in insect cells.
Sondermann P; Jacob U; Kutscher C; Frey J
Biochemistry; 1999 Jun; 38(26):8469-77. PubMed ID: 10387093
[TBL] [Abstract][Full Text] [Related]
47. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
Mattes MJ; Sharkey RM; Karacay H; Czuczman MS; Goldenberg DM
Clin Cancer Res; 2008 Oct; 14(19):6154-60. PubMed ID: 18829494
[TBL] [Abstract][Full Text] [Related]
48. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
[TBL] [Abstract][Full Text] [Related]
49. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
50. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
[TBL] [Abstract][Full Text] [Related]
51. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
[TBL] [Abstract][Full Text] [Related]
52. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
Pander J; Heusinkveld M; van der Straaten T; Jordanova ES; Baak-Pablo R; Gelderblom H; Morreau H; van der Burg SH; Guchelaar HJ; van Hall T
Clin Cancer Res; 2011 Sep; 17(17):5668-73. PubMed ID: 21788356
[TBL] [Abstract][Full Text] [Related]
53. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.
Li Y; Williams ME; Cousar JB; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2007 Sep; 179(6):4263-71. PubMed ID: 17785867
[TBL] [Abstract][Full Text] [Related]
54. CD81 is a novel immunotherapeutic target for B cell lymphoma.
Vences-Catalán F; Kuo CC; Rajapaksa R; Duault C; Andor N; Czerwinski DK; Levy R; Levy S
J Exp Med; 2019 Jul; 216(7):1497-1508. PubMed ID: 31123084
[TBL] [Abstract][Full Text] [Related]
55. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
56. FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas.
Camilleri-Broët S; Cassard L; Broët P; Delmer A; Le Touneau A; Diebold J; Fridman WH; Molina TJ; Sautès-Fridman C
Br J Haematol; 2004 Jan; 124(1):55-62. PubMed ID: 14675408
[TBL] [Abstract][Full Text] [Related]
57. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
58. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
59. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
[TBL] [Abstract][Full Text] [Related]
60. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
